Nastech Pharmaceutical is cutting 50 jobs in its second layoff in less than three months.
Nastech Pharmaceutical said Tuesday it will cut its workforce by nearly a third, as the company still seeks to steady itself after Procter & Gamble pulled out of a lucrative joint research effort late last year.
Some 50 employees “all the way across the company” will lose their jobs, mostly in Nastech’s Bothell offices, said president Gordon Brandt. Nastech currently employs 158.
The company will know specifically what jobs will be cut in a couple of weeks, Brandt said.
This is Nastech’s second round of layoffs in less than three months. In late November the firm announced plans to eliminate 72 jobs. Back then Nastech also said it would spin off an emerging technology subsidiary called MDRNA and focus in its mid-stage clinical programs.
Most Read Business Stories
- The penthouse atop Smith Tower is on the rental market for the first time
- Downtowns will be back, but Seattle has choices to make
- Boutique cruise line Windstar will move its Seattle headquarters to Miami
- Zillow’s price estimates are now cash offers in homebuying push
- US advisers endorse single-shot COVID-19 vaccine from J&J
“We need to continue to do belt-tightening,” Brandt said.
The new reductions will slow the company’s cash burn rate by at least $11 million in 2008, a Nastech statement said. The company expects key clinical data in the coming quarters that could enable it to pursue partnerships with other biotechs or pharmaceutical firms, Brandt said. The spinoff of MDRNA is also expected to bring in some revenue, he said.
Nastech shares closed at $2.22 on Tuesday, down 6.72 percent. The stock traded at more than $14 per share before Procter & Gamble abandoned a partnership to develop a nasal spray to treat osteoporosis.
Ángel González: 206-515-5644 or firstname.lastname@example.org